TNF Pharmaceuticals (TNFA) Competitors $0.20 +0.01 (+4.74%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$0.20 +0.00 (+1.44%) As of 05/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock TNFA vs. CTXR, BTAI, PMCB, MYNZ, CELZ, CARM, HCWB, CHRO, TLPH, and AIMDShould you be buying TNF Pharmaceuticals stock or one of its competitors? The main competitors of TNF Pharmaceuticals include Citius Pharmaceuticals (CTXR), BioXcel Therapeutics (BTAI), PharmaCyte Biotech (PMCB), Mainz Biomed (MYNZ), Creative Medical Technology (CELZ), Carisma Therapeutics (CARM), HCW Biologics (HCWB), Chromocell Therapeutics (CHRO), Talphera (TLPH), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. TNF Pharmaceuticals vs. Citius Pharmaceuticals BioXcel Therapeutics PharmaCyte Biotech Mainz Biomed Creative Medical Technology Carisma Therapeutics HCW Biologics Chromocell Therapeutics Talphera Ainos TNF Pharmaceuticals (NASDAQ:TNFA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment. Is TNFA or CTXR more profitable? Citius Pharmaceuticals' return on equity of -51.69% beat TNF Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TNF PharmaceuticalsN/A -180.71% -84.27% Citius Pharmaceuticals N/A -51.69%-37.60% Does the MarketBeat Community favor TNFA or CTXR? Citius Pharmaceuticals received 212 more outperform votes than TNF Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformTNF PharmaceuticalsN/AN/ACitius PharmaceuticalsOutperform Votes21262.54% Underperform Votes12737.46% Do institutionals and insiders believe in TNFA or CTXR? 9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.2% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, TNFA or CTXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTNF PharmaceuticalsN/AN/A-$4M-$11.45-0.02Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Does the media refer more to TNFA or CTXR? In the previous week, TNF Pharmaceuticals had 6 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 7 mentions for TNF Pharmaceuticals and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.89 beat TNF Pharmaceuticals' score of 0.15 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment TNF Pharmaceuticals Neutral Citius Pharmaceuticals Very Positive Do analysts recommend TNFA or CTXR? Citius Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 7,448.48%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than TNF Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility & risk, TNFA or CTXR? TNF Pharmaceuticals has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. SummaryCitius Pharmaceuticals beats TNF Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get TNF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNFA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNFA vs. The Competition Export to ExcelMetricTNF PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95M$2.60B$5.53B$7.93BDividend YieldN/A0.75%5.11%4.22%P/E Ratio-0.027.7322.5118.54Price / SalesN/A48.76397.62103.30Price / CashN/A15.7538.1834.62Price / Book0.033.766.734.25Net Income-$4M-$65.73M$3.22B$248.18M7 Day Performance-8.59%-0.16%1.38%1.03%1 Month Performance-50.22%-4.58%2.79%2.70%1 Year PerformanceN/A-12.29%15.41%4.05% TNF Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNFATNF PharmaceuticalsN/A$0.20+4.7%N/AN/A$1.95MN/A-0.026High Trading VolumeCTXRCitius Pharmaceuticals2.5858 of 5 stars$0.84-0.6%$54.50+6,357.3%-96.0%$9.03MN/A0.0020Positive NewsBTAIBioXcel Therapeutics4.4392 of 5 stars$1.96+4.8%$42.60+2,073.5%-95.6%$8.94M$2.27M-0.0690Upcoming EarningsPositive NewsGap UpPMCBPharmaCyte Biotech1.627 of 5 stars$1.29+5.7%N/A-44.8%$8.86MN/A2.434Gap UpMYNZMainz Biomed2.9746 of 5 stars$3.70+4.8%$14.00+278.4%-90.3%$8.58M$893,991.00-0.0630Gap UpHigh Trading VolumeCELZCreative Medical Technology1.1945 of 5 stars$1.95-1.0%N/A-56.5%$8.55M$11,000.00-0.515Upcoming EarningsPositive NewsGap UpCARMCarisma Therapeutics3.4418 of 5 stars$0.20-9.7%$1.93+843.6%-87.6%$8.53M$19.63M-0.1320Upcoming EarningsShort Interest ↓Positive NewsHCWBHCW Biologics1.0052 of 5 stars$7.58+9.8%N/A-85.7%$8.51M$2.57M-7.5840Gap DownCHROChromocell TherapeuticsN/A$1.35-0.7%N/A-29.4%$8.24MN/A-0.924News CoverageGap DownTLPHTalphera2.2639 of 5 stars$0.48-1.3%$4.33+803.5%-48.8%$8.20M$281,000.00-0.7019AIMDAinos0.5692 of 5 stars$0.54-1.7%N/A-48.1%$8.10M$20,729.00-0.3240 Related Companies and Tools Related Companies Citius Pharmaceuticals Alternatives BioXcel Therapeutics Alternatives PharmaCyte Biotech Alternatives Mainz Biomed Alternatives Creative Medical Technology Alternatives Carisma Therapeutics Alternatives HCW Biologics Alternatives Chromocell Therapeutics Alternatives Talphera Alternatives Ainos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNFA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
